ABSTRACT
OBJECTIVE： To evaluate the economics of the full coverage policy for hypoglycemic essential medicines in Taizhou city， and to provide reference for improving medicine accessibility and essential medicine system in China. METHODS： The electronic health records and financial input data of diabetic patients were extracted from different districts and counties of Taizhou city during 2009-2016. In cohort study design， taking the implementation time of each district and county’s policies as the breakpoint， the data recorded annually were processed as annual data， forming the cohort data for 1 year before （baseline year） and 3 years after the implementation of the policies. According to the choice of free medicines after the implementation of the policy， they were divided into policy group and control group. Propensity score matching was used to balance the differences between two groups to get the final sample， and then the economics of the policy was evaluated with the methods of difference-in-differences. The cost and benefit of implementation policy were calculated. RESULTS： Totally 14 744 people of each group were got by propensity score matching. The mean annual financial expenses on free medicine per capita were 263.8 yuan. Compared with baseline year， mean annual medicine expenses per capita reduced by the policy were 649.2 yuan， and mean annual hospitalization expenses per capita were 624.7 yuan. Thus the input-output ratio of the policy was 1 ∶ 4.8. CONCLUSIONS： The implementation of the policy is beneficial to reduce the cost burden of patients and economical. It can be popularized and sustained through scientific design combined with relevant policies.
ABSTRACT
@#This study aimed to review the availability of sugar-free medicine available in the market using the online Monthly Index of Medical Specialties (MIMS) Malaysia 2016. Data collection was obtained from product information (PI) for prescription medications contained in the MIMS Malaysia 2016. Concise information for each product was collected based on therapeutic class groupings. The therapeutic class obtained from PI was assigned to one of the 11 major therapeutic classes. PI that stated its use in paediatrics was further reviewed for the availability of sugar free ingredient. Each product was then allocated into the poison groups: Group B, Group C and Non-Scheduled Poison. A total of 282 PI items from 336 companies in MIMS Malaysia 2016 that satisfied our eligibility criteria were reviewed. Of the 282 PI items reviewed, most of the products, 169 (59.9%) were sugarbased product, while 87 (30.9%) of them belong to sugar free products. Our study found that most of the medicines reviewed in the MIMS Malaysia 2016 were under Group C (134 of total 282). There is still a high number of sugar-containing medicines despite the promotion of sugar-free medication. Therefore, consumers need to be educated on the use of sugar-free medicines in children to increase the demand and availability in the market.